Equities analysts predict that Allakos Inc (NASDAQ:ALLK) will announce earnings per share of ($0.50) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Allakos’ earnings, with the highest EPS estimate coming in at ($0.49) and the lowest estimate coming in at ($0.50). Allakos posted earnings per share of ($0.35) in the same quarter last year, which indicates a negative year-over-year growth rate of 42.9%. The business is expected to announce its next earnings results on Thursday, March 12th.
According to Zacks, analysts expect that Allakos will report full year earnings of ($1.88) per share for the current fiscal year, with EPS estimates ranging from ($1.88) to ($1.87). For the next financial year, analysts anticipate that the company will post earnings of ($2.58) per share, with EPS estimates ranging from ($2.98) to ($2.17). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for Allakos.
Allakos (NASDAQ:ALLK) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04).
ALLK traded down $0.18 during trading on Tuesday, reaching $120.89. 331,487 shares of the company traded hands, compared to its average volume of 453,779. Allakos has a 12-month low of $30.32 and a 12-month high of $139.99. The firm has a fifty day simple moving average of $85.05 and a 200 day simple moving average of $66.70. The company has a market cap of $5.71 billion, a P/E ratio of -54.95 and a beta of -1.13.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC bought a new position in shares of Allakos during the 3rd quarter valued at approximately $42,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Allakos during the 3rd quarter valued at approximately $113,000. Bank of Montreal Can bought a new position in shares of Allakos during the 2nd quarter valued at approximately $63,000. Amundi Pioneer Asset Management Inc. bought a new position in shares of Allakos during the 1st quarter valued at approximately $142,000. Finally, SG Americas Securities LLC boosted its position in shares of Allakos by 27.5% during the 2nd quarter. SG Americas Securities LLC now owns 4,819 shares of the company’s stock valued at $209,000 after acquiring an additional 1,040 shares during the last quarter. Hedge funds and other institutional investors own 68.68% of the company’s stock.
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Featured Article: Special Dividends
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.